CD33 and neoplasm: It is unclear whether targeting CD33 with a CAR would result in hepatic toxicity as seen with GO [19, 20], however, considering that administration of CAR T-cells has been associated with cytokine release syndrome and other potential off-tumor effects in patients [4], safety measures are here investigated.